Abstract

This research aims to investigate nifedipine and low molecular weight heparin clinical efficacy in cure patients with hypertension during pregnancy. A retrospective analysis of 180 patients with hypertension during pregnancy admitted to the obstetric ward of our hospital from December 2017 to December 2020 was selected. Among them, 90 patients with hypertension during pregnancy were treated with nifedipine combined with low molecular weight heparin (observation group). Nifedipine was used to treat 90 patients with pregnancy-induced hypertension (control group). Contrast the blood pressure, D-dimer, pregnancy-related complications and adverse events incidence in both groups before and after treatment were compared. The observation group clinical effective rate was 90 % while the control group was 70 % (p<0.05). The blood pressure and D-dimer of both groups decreased obviously after treatment, but the observation group decreased more significantly than it (p<0.01). The observation group incidence of pregnancy-related complications (uterine weakness, postpartum hemorrhage) was significantly lower than the other (p<0.05). There was no diversity in these two groups in incidence of fetal distress, placental abruption and neonatal asphyxia (p<0.05), both groups incidence of adverse reactions were almost the same and there was no statistical difference (p>0.05). Nifedipine and low molecular weight heparin in patients cure with hypertension during pregnancy can lower blood pressure and reduce the incidence of uterine asthenia, postpartum hemorrhage and other related complications without increasing patient’s incidence of adverse reactions. The medication is meaningful for clinical promotion.